ClinicalTrials.gg
RecruitingNCT04883515OBEGLUTUpdated Feb 6, 2026

Effects of Oral Glutamine Supplementation on Insulin Resistance and Functional Intestinal Disorders in Obese Patients.

An interventional study of Oral glutamine supplementation and Oral protein powder supplementation in Obesity and Insulin Resistance, sponsored by University Hospital, Rouen. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by University Hospital, Rouen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 476 studies in Obesity with a site in France — 112 open to participants now, 128 under way, 25 of them phase 3. Obesity · France.

Planned enrollment
147th of 355
110 · median 80
Started
2023
with 24 others
No phase
259 of 476
64 open now
Primary completion
2026-06
later than 26 of 127 live
Registered
324th of 476
by date

Among the 476 studies in Obesity with a site in France, this one is the 147th largest by planned enrollment of the 355 interventional ones that give a count, is one of 25 that started in 2023, is one of 259 with no phase, reaches primary completion later than 26 of the 127 other live ones, and was the 324th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

112 of the 476 studies in Obesity with a site in France are open now. Recruiting first, the newest first:

107 more — sign in →

All 112 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 476 studies in Obesity with a site in France, or all of them as a file.
02

Study summary

Obesity, which has a prevalence at 15% in France, is a major public health concern. Altered glycemic control and irritable bowel syndrome (IBS) are frequently observed in obese patients and lead to reduce the quality of life. In the last decades, the role of gut microbiota and intestinal permeability has been underlined in obesity, glycemic control and IBS. Interestingly, experimental and clinical data show that glutamine, an amino acid, is able to maintain or restore intestinal permeability in different conditions. We thus hypothesize that oral glutamine supplementation may restore gut barrier function contributing to improve glycemic control and IBS-symptoms. Our project will thus aim to evaluate the effects of 8 weeks - oral glutamine supplementation on glycemic control and IBS symptoms in obese patients in a blinded randomized controlled trial. Placebo group will received protein powder. 55 obese patients will enrolled in each arm and will received oral glutamine supplementation or protein powder (10g t.i.d.) during 8 weeks. Blood and feces samples and intestinal permeability assays will be performed at baseline (w0), after 8 weeks of supplementation (w8) and then after 8 weeks of a wash-out period (w16).

03

Conditions studied

  • Obesity
  • Insulin Resistance

Keywords

  • oral glutamine supplementation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged from 18 to 65 years
  • Patient with h grade II or III obesity ( equal or higher than 35 kg/m2)
  • Patient with insulino-resistance (fasting glycaemia ≥ 1g/l et \< 1.26 g/l)
  • Patient with irritable bowel syndrome (Rome IV criteria ≥ 2)

Exclusion criteria

Exclusion Criteria:

  • Patient with Known liver insufficiency ( \< 70%)
  • Patient with Known kidney failure ( \< 60 ml/mn)
  • Patient with Known intestinal diseases such as inflammatory bowel diseases
  • Vomiting patients (≥ 1/ day) during the last 4 weeks
  • Patient Previously received bariatric surgery or digestive surgery
  • Patient Using laxatives or protein powder during the 4 last weeks
  • On going Pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Oral glutamine supplementation

    patient will receive Oral glutamine supplementation 10 g Ter In Die during 8 weeks

    Dietary Supplement: Oral glutamine supplementation · Procedure: Insulin-resistance evaluation · Procedure: Functional intestinal disorders evaluation

  • Active comparator
    Oral protein powder supplementation

    patient will receive Oral protein powder supplementation10 g Ter In Die during 8 weeks

    Dietary Supplement: Oral protein powder supplementation · Procedure: Insulin-resistance evaluation · Procedure: Functional intestinal disorders evaluation

Interventions

  • Dietary supplementOral glutamine supplementation

    patient will receive oral glutamine supplementation 10 g Ter In Die during 8 weeks

  • Dietary supplementOral protein powder supplementation

    patient will receive oral protein powder supplementation10 g Ter In Die during 8 weeks

  • ProcedureInsulin-resistance evaluation

    Homeostasic model assessment of insulin resistance test will be performed at baseline, Week 8 and Week 16

  • ProcedureFunctional intestinal disorders evaluation

    Functional intestinal disorders will be measured by the IBS severity score and feces consistency by Bristol scale at baseline, Week 8 and Week 16

06

What researchers measure

Primary outcomes

  1. Change between Homeostasic model assessment of insulin resistance test value at baseline and week 8

    Time frame: Week 8

Secondary outcomes

  1. Change between Homeostasic model assessment of insulin resistance test value at baseline and week 16

    Time frame: Week 16

  2. Change between Homeostasic model assessment of insulin resistance test value at Week 8 and week 16

    Time frame: week 16

  3. Change between Irritable Bowel Syndrome (IBS) severity score at baseline and week 8

    Francis score will be used

    Time frame: Week 8

  4. Change between Irritable Bowel Syndrome (IBS) severity score at baseline and week 16

    Francis score will be used

    Time frame: Week 16

  5. Change between feces consistency at baseline and week 8

    bristol scale will be used

    Time frame: Week 8

  6. Change between feces consistency at baseline and week 16

    bristol scale will be used

    Time frame: Week 16

07

Study locations

1 of 1 sites recruiting
  • Rouen University Hospital
    Rouen, 76031, France
    Recruiting
    • Hélène LELANDAIS, MD · Contacthelene.lelandais@chu-rouen.fr · +3323288
    • Hélène LELANDAIS, MD · Principal investigator
    • Eglantine FERRAND-DEVOUGE, Dr · Sub investigator
    • Marie-Pierre TAVOLACCI, Dr · Sub investigator
    • André PETIT, Dr · Sub investigator
    • Najate ACHAMRAH, Dr · Sub investigator
    • Moïse COEFFIER, Dr · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jun 2026, 39 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 39 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2021
First posted
May 12, 2021
StartActual
Mar 1, 2023
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04883515
Responsible party
Sponsor
First posted
May 12, 2021
Start date
Mar 1, 2023
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Feb 6, 2026

Study contacts

Hélène LELANDAIS, MD
Contact
helene.lelandaix@chu-rouen.fr
+3323288 ext. 9065
Julien BLOT
Contact
julien.blot@chu-rouen.fr
+3323288 ext. 8265
Hélène LELANDAIS, MD
principal investigator · University Hospital, Rouen
Moïse COEFFIER, Pr
study director · University Hospital, Rouen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion